| 姜洁,刘浩楠.吉西他滨/白蛋白紫杉醇联合安罗替尼及PD-1抑制剂一线治疗晚期胰腺癌的疗效及安全性[J].安徽医药,待发表. |
| 吉西他滨/白蛋白紫杉醇联合安罗替尼及PD-1抑制剂一线治疗晚期胰腺癌的疗效及安全性 |
|
| 投稿时间：2024-02-26 录用日期：2024-05-16 |
| DOI： |
| 中文关键词: 胰腺癌 化疗 安罗替尼 PD-1抑制剂 疗效 安全性 |
| 英文关键词: |
| 基金项目:江苏省高层次卫生人才“六个一工程”A类项目（LGY2020006） |
|
| 摘要点击次数: 815 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要：目的 初步探讨吉西他滨/白蛋白紫杉醇（AG方案）联合安罗替尼及PD-1抑制剂一线治疗晚期胰腺癌的临床疗效及不良反应。方法 回顾性分析徐州医科大学附属医院2019年8月—2023年3月收治的50例晚期胰腺癌患者。根据治疗方案分为两组，其中化疗组（AG方案）26例患者，联合治疗组（AG方案联合安罗替尼及PD-1抑制剂）24例患者。分析比较两组患者的无进展生存时间（PFS）、总生存时间（OS）、客观缓解率（ORR）、疾病控制率（DCR）和不良反应发生情况。使用Kaplan-Meier方法绘制两组患者的生存曲线，并采用Log-rank检验来比较两组的生存差异。使用Cox回归模型进行单因素和多因素分析来确定影响OS的独立危险因素。结果 联合治疗组患者的中位PFS明显长于化疗组（5.6个月vs 4.4个月，P=0.012），且中位OS也明显长于化疗组（12.8个月vs 7.8个月，P=0.007）。两组患者的ORR未见明显差异（33.3% vs 23.1%，P=0.420），联合治疗组的DCR（83.3% vs 57.7%，P=0.048）显著优于化疗组。两组患者均以1-2级不良反应为主，无不良反应相关死亡事件发生。结论 与单纯化疗相比，AG方案联合安罗替尼及PD-1抑制剂一线治疗晚期胰腺癌的疗效更好，且不良反应可控。 |
| 英文摘要: |
| Abstract: Objective To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) combined with anlotinib and PD-1 inhibitor as first-line treatment for advanced pancreatic cancer (PC). Methods Fifty patients with advanced PC treated in Affiliated Hospital of Xuzhou Medical University from August 2019-March 2023 were retrospectively analyzed. According to the treatment regimen, the patients were divided into two groups, including 26 patients in the chemotherapy group (AG regimen) and 24 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitor). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were compared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by Log-rank test. Univariate and multivariate analyses were performed using Cox proportional hazard regression models to identify independent risk factors influencing prognosis. Results The median OS and PFS in the combined treatment group group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.8 months, P=0.007; PFS, 5.6 vs. 4.4 months, P=0.012). There was no significant difference in ORR between the two groups (33.3% vs. 23.1%, P=0.420), and the DCR in the combined treatment group (83.3% vs. 57.7%, P=0.048) was significantly better than that in the chemotherapy group. Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction related deaths occurred. Conclusion Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitor has better efficacy in the first-line treatment of advanced PC, and the adverse reactions are controllable. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
